Barancik M, Htun P, Schaper W
Department of Experimental Cardiology, Max-Planck-Institute for Physiological and Clinical Research, Bad Nauheim, Germany.
J Cardiovasc Pharmacol. 1999 Aug;34(2):182-90. doi: 10.1097/00005344-199908000-00002.
We report that okadaic acid (OA), a known inhibitor of Ser/Thr phosphatases, protects pig myocardium against ischemic injury in an in vivo model and stimulates the activities of stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). When OA was directly infused into the subsequently ischemic myocardium for 60 min before a 60-min period of coronary occlusion followed by reperfusion, infarct size was reduced from a control value of 83.4 +/- 2.8% of the risk region to 40.7 +/- 9.1%. When OA was infused for 10 min before a 5-min occlusion and during 45 min thereafter, infarct size was reduced to 26.5%. In a separate set of similar experiments, we pretreated pig hearts in vivo with the protein-synthesis inhibitor and known activator of SAPK/JNK, anisomycin (AN), and found that this compound also significantly reduced infarct size from 83.4 +/- 2.8.1% to 48.1 +/- 5.1%. For in vitro assays, OA (600 nM), AN (500 microM), or solvent (KHB) were locally infused into the left ventricular myocardium, and biopsies from in situ beating hearts were obtained after 10, 30, and 60 min of infusion. The activities of Ser/Thr phosphatases (PPases), especially PP-2A, were significantly decreased after OA infusion. OA infusion increased the activity (in-gel phosphorylation of N-terminal c-Jun1-135) of both 46- and 55-kDa SAPK/JNKs (twofold to threefold, 30 and 60 min of infusion), and this increase correlated well with the observed decrease of PPase activities. Western blot analysis with a phosphospecific SAPK/JNK (Thr 183/Tyr 185) antibody showed an increased content of the phosphorylated forms after OA treatment. We observed significant stimulation of SAPK/JNK activity also after AN treatment (threefold to fourfold, after 30 min of infusion). In contrast to the SAPK/JNKs, the infusion of both OA and AN did not significantly change the activities and phosphorylation of extracellular signal-related kinases (ERKs) and p38-MAPK. The findings that the protective effect of both OA and AN correlates with increased activity of SAPK/JNKs suggest the involvement of these enzymes in the mechanism of cardioprotection.
我们报告称,冈田酸(OA)是一种已知的丝氨酸/苏氨酸磷酸酶抑制剂,在体内模型中可保护猪心肌免受缺血性损伤,并刺激应激激活蛋白激酶/c-Jun氨基末端激酶(SAPKs/JNKs)的活性。在冠状动脉闭塞60分钟随后再灌注之前,将OA直接注入随后发生缺血的心肌60分钟,梗死面积从风险区域的对照值83.4±2.8%降至40.7±9.1%。在5分钟闭塞前10分钟及之后45分钟内注入OA,梗死面积降至26.5%。在另一组类似实验中,我们在体内用蛋白质合成抑制剂及已知的SAPK/JNK激活剂茴香霉素(AN)预处理猪心脏,发现该化合物也显著降低了梗死面积,从83.4±2.8%降至48.1±5.1%。对于体外测定,将OA(600 nM)、AN(500 μM)或溶剂(KHB)局部注入左心室心肌,在注入10、30和60分钟后从原位跳动的心脏获取活检组织。注入OA后,丝氨酸/苏氨酸磷酸酶(PPases),尤其是PP-2A的活性显著降低。注入OA增加了46 kDa和55 kDa的SAPK/JNKs的活性(氨基末端c-Jun1-135的凝胶内磷酸化)(注入30和60分钟时增加了两倍至三倍),这种增加与观察到的PPase活性降低密切相关。用磷酸特异性SAPK/JNK(苏氨酸183/酪氨酸185)抗体进行的蛋白质印迹分析显示,OA处理后磷酸化形式的含量增加。在AN处理后(注入30分钟后增加了三倍至四倍),我们也观察到SAPK/JNK活性受到显著刺激。与SAPK/JNKs相反,注入OA和AN均未显著改变细胞外信号相关激酶(ERKs)和p38丝裂原活化蛋白激酶(p38-MAPK)的活性和磷酸化。OA和AN的保护作用均与SAPK/JNKs活性增加相关的这一发现表明,这些酶参与了心脏保护机制。